Your browser is no longer supported. Please, upgrade your browser.
Settings
XENE Xenon Pharmaceuticals Inc. daily Stock Chart
XENE [NASD]
Xenon Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-1.68 Insider Own2.70% Shs Outstand17.78M Perf Week-1.30%
Market Cap67.56M Forward P/E- EPS next Y-0.25 Insider Trans- Shs Float15.33M Perf Month-3.80%
Income-27.30M PEG- EPS next Q-0.39 Inst Own64.60% Short Float1.47% Perf Quarter-16.48%
Sales1.20M P/S56.30 EPS this Y-34.60% Inst Trans-3.19% Short Ratio2.52 Perf Half Y-52.50%
Book/sh3.19 P/B1.19 EPS next Y62.70% ROA-42.40% Target Price9.13 Perf Year-39.68%
Cash/sh3.27 P/C1.16 EPS next 5Y- ROE-44.80% 52W Range3.65 - 9.95 Perf YTD-50.65%
Dividend- P/FCF- EPS past 5Y-10.90% ROI-38.80% 52W High-61.81% Beta-
Dividend %- Quick Ratio16.50 Sales past 5Y-23.60% Gross Margin- 52W Low4.11% ATR0.19
Employees88 Current Ratio16.50 Sales Q/Q-97.30% Oper. Margin- RSI (14)44.15 Volatility5.64% 5.02%
OptionableNo Debt/Eq0.00 EPS Q/Q-84.80% Profit Margin- Rel Volume0.73 Prev Close4.10
ShortableYes LT Debt/Eq0.00 EarningsAug 08 AMC Payout- Avg Volume89.37K Price3.80
Recom1.30 SMA20-2.81% SMA50-4.29% SMA200-44.08% Volume100,922 Change-7.32%
Mar-13-17Initiated Jefferies Buy $13
Oct-21-16Initiated Stifel Buy $18
Sep-26-16Initiated Guggenheim Buy $20
Apr-14-16Reiterated Jefferies Buy $10 → $13
Oct-30-15Resumed Jefferies Buy
Dec-02-14Initiated Canaccord Genuity Buy $15
Jun-02-17 04:03PM  Xenon Pharmaceuticals to Present at the Jefferies 2017 Healthcare Conference GlobeNewswire
09:48AM  Xenon Pharmaceuticals, Inc. :XENE-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
May-11-17 08:59AM  Edited Transcript of XENE earnings conference call or presentation 9-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-09-17 06:58PM  Xenon Pharmaceuticals reports 1Q loss Associated Press
04:03PM  Xenon Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
10:15AM  Investor Network: Xenon Pharmaceuticals Inc. to Host Earnings Call Accesswire
Apr-28-17 04:03PM  Xenon Pharmaceuticals to Present at the 2017 Bloom Burton & Co. Healthcare Investor Conference GlobeNewswire
09:35AM  Nuventra founder inks deal for new venture that could be worth as much as $49 million American City Business Journals
Apr-26-17 06:30AM  Xenon Expands Ion Channel Neurology Pipeline with Acquisition of New Potassium Channel Modulator for the Treatment of Epilepsy GlobeNewswire
Apr-06-17 09:32AM  3 of the Best & Worst Performing Drug Stocks of Q1 Zacks
Mar-29-17 08:15AM  Biotech Stock Roundup: Regeneron, Tesaro Drugs Approved, Vertex Scores Big in Study -5.75%
Mar-27-17 09:30AM  Xenon Pharmaceuticals Falls as Acne Drug Fails Study, Pulse Biosciences Submits 510(k) to FDA Accesswire
Mar-24-17 04:48PM  XENON PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -52.79%
09:00AM  Xenon Pharma Dumps Acne Drug After Study Failure Investopedia
07:17AM  Xenon Pharmaceuticals' acne drug fails mid-stage study Reuters
06:41AM  Xenon Pharmaceuticals' acne drug fails mid-stage study Reuters
06:30AM  Xenon Pharmaceuticals Announces XEN801 Did Not Meet Efficacy Endpoints in Phase 2 Clinical Trial in Patients with Moderate to Severe Acne GlobeNewswire
Mar-20-17 08:57AM  Xenon Pharmaceuticals, Inc. :XENE-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Capital Cube
Mar-15-17 12:08PM  Xenon Pharmaceuticals, Inc. :XENE-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017 Capital Cube
Mar-14-17 04:10PM  XENON PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers
01:04PM  XENON PHARMACEUTICALS INC. Financials
Mar-13-17 06:21AM  Coverage initiated on Xenon Pharmaceuticals by Jefferies
Mar-09-17 04:47PM  XENON PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
02:53PM  Edited Transcript of XENE earnings conference call or presentation 8-Mar-17 9:30pm GMT Thomson Reuters StreetEvents
Mar-08-17 04:30PM  Xenon Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today
04:15PM  XENON PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
04:01PM  Xenon Pharmaceuticals Reports 2016 Financial Results and Provides Corporate Update GlobeNewswire
07:07AM  Q4 2016 Xenon Pharmaceuticals Inc Earnings Release - After Market Close
Mar-01-17 04:01PM  Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2016 Financial Results and Provide Corporate Update GlobeNewswire
Jan-08-17 08:00PM  Xenon Pharmaceuticals Outlines Key Milestones for 2017 GlobeNewswire
Jan-03-17 05:07PM  XENON PHARMACEUTICALS INC. Files SEC form 8-K, Other Events
Dec-20-16 12:03AM  How Xenon Pharmaceuticals Inc (XENE) Stacks Up Against Its Peers at Insider Monkey
Dec-01-16 03:39PM  Wilbur Ross Sells 2 Holdings, Trims Another
Nov-28-16 03:52PM  Edited Transcript of XENE earnings conference call or presentation 3-Nov-16 8:30pm GMT -5.49%
Nov-08-16 04:02PM  Xenon Pharmaceuticals to Present at the Stifel 2016 Healthcare Conference GlobeNewswire
10:47AM  Xenon Pharmaceuticals, Inc. :XENE-US: Earnings Analysis: Q3, 2016 By the Numbers : November 8, 2016
Nov-03-16 06:21PM  Xenon Pharmaceuticals reports 3Q loss
04:30PM  Xenon Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today
04:21PM  XENON PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
04:02PM  Xenon Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update GlobeNewswire
07:07AM  Q3 2016 Xenon Pharmaceuticals Inc Earnings Release - After Market Close
Oct-27-16 04:15PM  Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2016 Financial Results and Provide Corporate Update GlobeNewswire
Sep-27-16 04:38PM  XENON PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex
04:10PM  Xenon Pharmaceuticals Appoints Dawn Svoronos to Its Board of Directors GlobeNewswire
Sep-13-16 04:02PM  Xenon Pharmaceuticals Announces Exercise in Full of Option to Purchase Additional Shares and Closing of $34.5 Million Public Offering GlobeNewswire
Sep-09-16 06:05AM  XENON PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Sep-08-16 09:01AM  Xenon Pharmaceuticals Announces Pricing of $30 Million Public Offering of Common Shares GlobeNewswire
Sep-07-16 04:32PM  Xenon Pharmaceuticals Announces Proposed Public Offering of Common Shares GlobeNewswire
Aug-11-16 10:35AM  Xenon Pharmaceuticals, Inc. :XENE-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016
Aug-08-16 03:19PM  Edited Transcript of XENE earnings conference call or presentation 3-Aug-16 8:30pm GMT
Aug-03-16 05:59PM  Xenon Pharmaceuticals reports 2Q loss
04:17PM  Xenon Expects XEN801 Results In Q1 2017, Delayed One Quarter
04:16PM  XENON PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
04:02PM  Xenon Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update GlobeNewswire
07:07AM  Q2 2016 Xenon Pharmaceuticals Inc Earnings Release - After Market Close
Aug-02-16 04:05PM  Xenon Pharmaceuticals to Present at the Canaccord Genuity 36th Annual Growth Conference GlobeNewswire
Jul-25-16 04:35PM  Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2016 Financial Results and Provide Corporate Update GlobeNewswire
Jun-23-16 05:48AM  Billionaire Wilbur Ross Is Against Brexit; Here Are His Funds Top 13F Holdings at Insider Monkey
Jun-08-16 07:45AM  Xenon Pharmaceuticals Presents Corporate Update and Highlights Its Proprietary Therapeutic Programs at the Jefferies 2016 Healthcare Conference GlobeNewswire
Jun-03-16 04:32PM  XENON PHARMACEUTICALS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-02-16 08:00AM  Xenon Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference GlobeNewswire +5.13%
May-17-16 04:34PM  Xenon Pharmaceuticals, Inc. :XENE-US: Earnings Analysis: Q1, 2016 By the Numbers
May-10-16 05:28PM  Xenon Pharmaceuticals reports 1Q loss
05:07PM  XENON PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
04:30PM  Xenon Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today
04:01PM  Xenon Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update GlobeNewswire
07:07AM  Q1 2016 Xenon Pharmaceuticals Inc Earnings Release - After Market Close
May-02-16 04:01PM  Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2016 Financial Results and Provide Corporate Update GlobeNewswire
Apr-07-16 11:41AM  Edited Transcript of XENE earnings conference call or presentation 8-Mar-16 9:30pm GMT
Apr-04-16 04:30PM  Xenon Names Dr. Raymond J. Winquist as Head, Translational Research GlobeNewswire
Mar-31-16 04:40PM  XENON PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits +5.59%
04:30PM  Xenon Pharmaceuticals to Provide Business and Milestone Update at Needham Healthcare Conference GlobeNewswire
Mar-15-16 08:00AM  Xenon and Genentech Extend Collaborations Focused on Pain GlobeNewswire
Mar-14-16 10:59AM  Xenon Pharmaceuticals, Inc. :XENE-US: Earnings Analysis: Q4, 2015 By the Numbers
Mar-11-16 05:04PM  XENON PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers
Mar-09-16 04:59PM  XENON PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-08-16 05:04PM  XENON PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
04:30PM  Xenon Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today
04:22PM  Xenon Pharmaceuticals reports 4Q loss
04:00PM  Xenon Pharmaceuticals Reports 2015 Financial Results and Provides Corporate Update GlobeNewswire
07:07AM  Q4 2015 Xenon Pharmaceuticals Inc Earnings Release - After Market Close
Mar-01-16 07:37PM  Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2015 Financial Results and Provide Corporate Update GlobeNewswire
Feb-18-16 04:24PM  Xenon Pharmaceuticals, Inc.: Price momentum supported by strong fundamentals -8.06%
Feb-10-16 08:00AM  Xenon Initiates Phase 2 Clinical Trial of XEN801 to Treat Moderate to Severe Acne GlobeNewswire
Feb-09-16 08:00AM  Xenon Names Dr. James R. Empfield Senior Vice President, Drug Discovery GlobeNewswire
Jan-11-16 08:00AM  Xenon Outlines Key Milestones for 2016 GlobeNewswire
Dec-23-15 01:08PM  Xenon Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers
Dec-17-15 02:08PM  Xenon and Genentech Publish in Science the 3-D Crystal Structure of a Novel Nav1.7 Compound Binding Site Enabling the Development of Potent Selective Inhibitors to Treat Pain GlobeNewswire
Dec-08-15 10:59AM  Should You Buy Energy Focus Inc (EFOI)? at Insider Monkey
Nov-27-15 08:32AM  Marinus Pharmaceuticals Inc (MRNS): Are Hedge Funds Right About This Stock? at Insider Monkey
Nov-24-15 01:07PM  How Is Smart Money Trading Xenon Pharmaceuticals Inc (XENE)? at Insider Monkey
Nov-12-15 04:30PM  Xenon Pharmaceuticals to Present at the Stifel 2015 Healthcare Conference GlobeNewswire
Nov-10-15 05:00PM  Xenon Pharmaceuticals Inc Earnings Call scheduled for 5:00 pm ET today
04:47PM  Xenon Pharmaceuticals reports 3Q loss
04:32PM  XENON PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
04:30PM  Xenon Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Corporate Update GlobeNewswire
07:07AM  Q3 2015 Xenon Pharmaceuticals Inc Earnings Release - After Market Close
Nov-05-15 05:00PM  Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2015 Financial Results and Provide Corporate Update GlobeNewswire
Oct-22-15 08:00AM  Xenon Announces Its Partner Genentech Has Advanced GDC-0310, a Second Nav1.7 Inhibitor for Pain, Into Clinical Development GlobeNewswire
Sep-24-15 08:30AM  Xenon Pharmaceuticals Announces Initiation of XEN801 Phase 1 Clinical Trial GlobeNewswire
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing differentiated therapeutics for orphan indications in Canada. The company uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. It offers Glybera, a gene therapy product for the treatment of patients with orphan lipid disorder lipoprotein lipase deficiency. The company is also developing TV-45070, which is in Phase IIb clinical trials in patients with post-herpetic neuralgia; GDC-0276 and GDC-0310 that completed Phase I clinical trials for the treatment of pain; and XEN801, a stearoyl Co-A desaturase-1 inhibitor that is in Phase II clinical trials in patients with moderate to severe facial acne. Its preclinical product candidate includes XEN901, a selective Nav1.6 sodium channel inhibitor for the treatment of childhood epilepsy disorders. Xenon Pharmaceuticals Inc. has collaboration agreements with Teva Pharmaceutical Industries Ltd.; Genentech, Inc.; uniQure Biopharma B.V.; and Merck & Co., Inc. The company was founded in 1996 and is headquartered in Burnaby, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BVF PARTNERS L P/IL10% OwnerJun 22Buy4.008,26333,0521,588,237Jun 23 07:16 PM
BVF PARTNERS L P/IL10% OwnerJun 21Buy4.0012,14848,5921,583,712Jun 23 07:16 PM
TARNOW MICHAEL MDirectorJun 19Option Exercise3.511,0283,60856,195Jun 20 04:37 PM
BVF PARTNERS L P/IL10% OwnerJun 19Buy3.853,59513,8411,577,332Jun 19 07:33 PM
BVF PARTNERS L P/IL10% OwnerJun 16Buy3.8511,03442,4811,575,365Jun 19 07:33 PM
BVF PARTNERS L P/IL10% OwnerJun 15Buy3.8411,77945,1961,569,268Jun 19 07:33 PM
BVF PARTNERS L P/IL10% OwnerJun 07Buy3.85207,789800,2371,562,494Jun 08 06:58 PM
BVF PARTNERS L P/IL10% OwnerJun 06Buy3.75150,909565,9091,449,048Jun 08 06:58 PM
ROBIN SHERRINGTONSVP Bus. & Corp. DevelopmentMay 12Option Exercise3.212,0576,6036,079May 16 04:32 PM
Hayden Michael RDirectorMar 14Option Exercise3.4411,83040,71130,348Mar 15 07:53 PM
Hayden Michael RDirectorMar 14Option Exercise3.7348,868182,200146,187Mar 15 07:53 PM
HOLLER FRANK ADirectorDec 15Sale7.8530,000235,500115,869Dec 19 05:07 PM
TARNOW MICHAEL MDirectorDec 12Option Exercise3.2114,40346,23469,570Dec 13 04:57 PM
PATOU GARYDirectorDec 06Option Exercise3.2112,34539,62716,431Dec 08 04:52 PM
AZAB MOHAMMADDirectorDec 01Option Exercise3.2112,34539,62717,283Dec 02 06:05 PM
HOLLER FRANK ADirectorAug 19Sale7.6511,93891,338145,869Aug 23 04:51 PM
HOLLER FRANK ADirectorAug 18Sale7.709,59973,912157,807Aug 18 08:24 PM
HOLLER FRANK ADirectorAug 17Sale7.891,60012,624167,406Aug 18 08:24 PM
HOLLER FRANK ADirectorAug 16Sale8.256,86356,620169,006Aug 18 08:24 PM
PIMSTONE SIMON N.President & CEOJul 29Option Exercise3.3012,34540,739216,550Aug 02 05:10 PM